Background
Methods
Patient characteristics and eligibility criteria
Patient no. | Age | Sex | Previous therapy | PS | Pathological diagnosis (WHO grade) |
---|---|---|---|---|---|
1
|
69
|
M
|
ST, CT
|
1
|
GBM (IV)
|
2
|
49
|
M
|
ST, CT, RT
|
0
|
AO (III)
|
3
|
38
|
M
|
ST, CT, RT
|
2
|
GBM (IV)
|
4
|
32
|
F
|
CT, RT,
|
2
|
AA (III)
|
5
|
61
|
M
|
ST, CT, RT
|
1
|
GBM (IV)
|
6
|
32
|
M
|
ST, CT, RT
|
1
|
GBM (IV)
|
7
|
73
|
M
|
ST, CT, RT
|
1
|
GBM (IV)
|
8
|
53
|
F
|
ST, CT,
|
1
|
GBM (IV)
|
9
|
31
|
M
|
ST, CT,
|
1
|
GBM (IV)
|
Preparation of DCs and peptides
IL-12p70 production assay
Tumor antigens and other antigens in tumor tissues prior to vaccination
Clinical and immunological monitoring
ELISPOT assay
Intracellular cytokine staining
DTH reactions
Statistical analysis
Results
Characterization of tumor antigen expression
Patient | hHLA-typing | Tumor antigen expression | HLA-class Ia
|
---|---|---|---|
1
|
A*2402
|
N. D.
|
N. D.
b
|
2
|
A*2402
|
5/5 (M1, M3, HER2, gp100, WT-1)
|
++
|
3
|
A*2402
|
5/5
|
+
|
4
|
A*2402
|
N. D.
|
N. D.
|
5
|
A*2402
|
3/5 (M3, HER2, WT-1)
|
+
|
6
|
A*2402
|
5/5
|
+
|
7
|
A*0201
|
5/5
|
+
|
8
|
A*2402
|
N. D.
|
N. D.
|
9
|
A*2402
|
5/5
|
+
|
DC production efficiency and characterization
Case numbers | Starting total cell no. (×109 ) | Optiprep (CD14+ %) | DC rate (%)* (lin-HLA-DR+) | Total DC numbers (×108 ) | Recovery rate (%) | DC1/DC2 ratio | Il-12p70 level (pg/ml) | |
---|---|---|---|---|---|---|---|---|
pre | post | |||||||
9
|
6.50±3.4
|
11.9±9.4
|
44.6±21.8
|
56.1±19.0
|
4.22±1.7
|
8.79±5.1
|
35.6±39.6
|
1025±443
|
Markers | Frequency (%)* | Markers | Frequency (%) | Markers | Frequency (%) |
---|---|---|---|---|---|
CD1a
|
16.3±13.2
|
CD80
|
92.4±15.5
|
CMRF44
|
3.7±2.4
|
CD11c
|
99.3±0.6
|
CD83
|
44.7±19.5
|
CMRF56
|
37.1±11.2
|
CD33
|
7.0±3.8
|
CD86
|
99.6±0.3
|
E-cadherin
|
13.1±7.4
|
CD40
|
95.9±5.1
|
CD205
|
73.9±12.1
|
CCR7
|
6.0±1.9
|
CD54
|
99.3±1.2
|
CD207
|
92.3±11.6
|
HLA-class I
|
99.0±1.2
|
ELISPOT assay
Patient no. | DC injection (times) | Side effect | ELISPOT | DTH | Th1/Th2 balancea
| Response | ||
---|---|---|---|---|---|---|---|---|
Peptide | DC | KLH | ||||||
1
|
1×10
7
(12)
|
1/5 (MAGE-1)
|
+
|
+
|
9.38
|
PD
| ||
2
|
1×10
7
(24)
|
4/5 (WT1-1, 1–2, MAGE-1, 3)
|
++
|
++
|
+++
|
0.3
|
SD
| |
3
|
1×10
7
(4)
|
N. D.
b
|
9.67
|
PD
| ||||
4
|
2×10
7
(5)
|
Hepatic (II)
|
3/5 (WT1-1, 1–2, MAGE-3)
|
4.09
|
PD
| |||
5
|
2×10
7
(6)
|
0
|
+
|
6.07
|
PD
| |||
6
|
2×10
7
(4)
|
0
|
2.77
|
PD
| ||||
7
|
5×10
7
(7)
|
1/5 (gp100)
|
+
|
7.08
|
PD
| |||
8
|
5×10
7
(6)
|
3/5 (WT1-2, HER2, MAGE-3)
|
71.4
|
PD
| ||||
9
|
5×10
7
(6)
|
2/5 (MAGE-1, 3)
|
++
|
+
|
+
|
7.55
|
PD
|